InspireMD (NSPR) Stock Overview
A medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NSPR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Top Community Narratives
NSPR | InspireMD Q2 2026: What They Said vs. What They Did
View narrative
InspireMD, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.77 |
| 52 Week High | US$2.57 |
| 52 Week Low | US$0.63 |
| Beta | 0.82 |
| 1 Month Change | -14.71% |
| 3 Month Change | 7.16% |
| 1 Year Change | -68.68% |
| 3 Year Change | -76.31% |
| 5 Year Change | -82.32% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
NSPR | InspireMD Q2 2026: What They Said vs. What They Did
The Gap Report: InspireMD, Inc. (NSPR) Q2 2026 (may 4 - aug 17) InspireMD reported second quarter 2026 results on August 17, 2026, against a backdrop that made the May call look almost optimistic by comparison.Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. By way of example, InspireMD...We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...InspireMD: Revolutionizing The Field Of Vascular Stenting
InspireMD develops and commercializes proprietary stent designs with a proprietary mesh. The Company seeks to change the SoC in the treatment of CAD and other invasive indications utilizing an integrated embolic protection stent platform. The Company’s commercialized products are CE mark approved but not approved for sale in the U.S. The Company has initiated a U.S. registrational IDE clinical trial for CGuard EPS in July 2021.Shareholder Returns
| NSPR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.8% | 1.6% | -0.2% |
| 1Y | -68.7% | -16.2% | 12.1% |
Return vs Industry: NSPR underperformed the US Medical Equipment industry which returned -16.3% over the past year.
Return vs Market: NSPR underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| NSPR volatility | |
|---|---|
| NSPR Average Weekly Movement | 9.2% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NSPR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NSPR's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 127 | Marvin Slosman | www.inspiremd.com |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.
InspireMD, Inc. Fundamentals Summary
| NSPR fundamental statistics | |
|---|---|
| Market cap | US$35.68m |
| Earnings (TTM) | -US$52.48m |
| Revenue (TTM) | US$10.84m |
Is NSPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NSPR income statement (TTM) | |
|---|---|
| Revenue | US$10.84m |
| Cost of Revenue | US$8.88m |
| Gross Profit | US$1.96m |
| Other Expenses | US$54.44m |
| Earnings | -US$52.48m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 18.05% |
| Net Profit Margin | -484.11% |
| Debt/Equity Ratio | 0% |
How did NSPR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 01:03 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InspireMD, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Jose De Jesus Haresco | Citizens JMP Securities, LLC |
| Frank Takkinen | Lake Street Capital Markets, LLC |